Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.

Saved in:
Bibliographic Details
Title: Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.
Authors: Alduaij W; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Sehn LH; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Champagne JN; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Hematology and Medical Oncology, Hôpital du Sacre-Coeur de Montréal, Montreal, QC, Canada., Collinge B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Ben-Neriah S; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Jiang A; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Hilton LK; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Boyle M; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Meissner B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Slack GW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Farinha P; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Craig JW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology, University of Virginia Health System, Charlottesville, VA., Savage KJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Villa D; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Gerrie AS; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Freeman CL; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Blood and Marrow Transplant and Cellular Therapy, Moffitt Cancer Center, Tampa, FL., Mungall AJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada., Steidl C; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Source: Blood advances [Blood Adv] 2026 Jan 27; Vol. 10 (2), pp. 320-333.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025017282